Guangzhou Cedicine Biotechnology

Guangzhou Cedicine Biotechnology is a biopharmaceutical company based in China that focuses on the development of innovative multi-specific antibody-drug conjugates (ADCs) for oncology. The company leverages its proprietary Ab-Drug platform, which enables the creation of site-specific, stable, and highly potent conjugates designed to improve the therapeutic window of cancer treatments. Its lead programs, including SCK-01 and SCK-02, target validated oncology markers such as HER2, HER3, and Claudin 18.2 to address unmet needs in solid tumors. Founded in 2022 by Dr. Wei-Dong Li, Cedicine has quickly attracted significant investment from prominent venture capital firms like Qiming Venture Partners. The company is currently in the pre-clinical and IND-enabling stages, moving its primary assets toward global clinical development.